Hisamitsu Overactive Bladder Transdermal Drug To Enter Phase III Trial
This article was originally published in PharmAsia News
Executive Summary
Japan's largest transdermal drug maker Hisamitsu plans to start a domestic Phase III trial for HOB-294 (transdermal oxybutynin) for overactive bladder. A Phase II trial has shown improvement in symptoms such as urination urgency and pollakiuria. Hisamitsu aims to start the subsequent trial next year. Oxybutynin is developed by French drug giant Sanofi-Aventis. (Click here for more - Japanese language